Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Classic Galactosemia
Interventions: AT-007, Placebo; Drug
Lead sponsor: Applied Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Anaheim, California • Atlanta, Georgia • Boston, Massachusetts + 1 more

Conditions: Healthy
Interventions: PF-04308515, Placebo, PF-04308515 Tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Asthma
Interventions: NO2 Scrubber, HEPA filter, Control; Other
Lead sponsor: Yale University; Other
Eligibility: 5 Years to 11 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neoplasm Metastasis, Non-Small Cell Lung Cancer
Interventions: zongertinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more

Conditions: Healthy
Interventions: LY2409021; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
Interventions: Dabrafenib, Trametinib, Pembrolizumab, Pulsed Stereotactic Ablative Radiotherapy, Ethos; Drug · Biological · Radiation + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
Interventions: Ice, Normal Saline Solution; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Advanced Solid Tumor Cancer
Interventions: X-PACT; Combination Product
Lead sponsor: Immunolight, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Charlotte, North Carolina • Durham, North Carolina + 1 more

Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Interventions: OR2805, Cemiplimab, Docetaxel; Drug
Lead sponsor: OncoResponse, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Austin, Texas • San Antonio, Texas

Conditions: Neoplasms
Interventions: DSP-0337; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Indianapolis, Indiana • Detroit, Michigan • San Antonio, Texas + 1 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions: FlorenceM (US) and FlorenceX (UK), Insulin pump therapy; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 6 Years to 18 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Hartford, Connecticut + 2 more

Conditions: Cerebral Aneurysm, Stroke, Vasospasm, Cerebral, Subarachnoid Hemorrhage, Aneurysmal, Aneurysmal Subarachnoid Hemorrhage, Cerebral Ischemia
Interventions: Transcranial Doppler; Diagnostic Test
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Adult Influenza Vaccinations, Adult PPSV Vaccinations, Adult Tdap/Td Vaccinations
Interventions: Pillar 1: Convenient Vaccination Services, Pillar 2: Patient notification, Pillar 3: Enhanced Office Systems, Pillar 4: Motivation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 70,549 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Healthy
Interventions: JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hip Fracture
Interventions: Nutrition, PUSH, PULSE; Dietary Supplement · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Farmington, Connecticut • Baltimore, Maryland • Lebanon, New Hampshire + 1 more

Conditions: Leukodystrophy, Globoid Cell
Interventions: PBKR03; Biological
Lead sponsor: Gemma Biotherapeutics; Industry
Eligibility: 1 Month to 9 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Allergic Conjunctivitis
Interventions: REGN-2Cat, Freneslerbart, Mevonlerbart, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 8 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Long Beach, California • Andover, Massachusetts

Conditions: Prostate Carcinoma
Interventions: Survey Administration, Tomato-Soy Juice; Other · Dietary Supplement
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetic Macular Edema, Uveitic Macular Edema
Interventions: RO7200220, Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Beverly Hills, California • Oxnard, California • Palm Desert, California + 16 more

Conditions: Type 1 Diabetes, Diabetes in Children
Interventions: T1D Parent Check-in; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eating Behavior, Body Image, Diet Habit, Dietary Habits
Interventions: Internal Cues, External Cues; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 26 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
Interventions: MCLA-145, Pembrolizumab (Keytruda); Drug
Lead sponsor: Merus B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York

Conditions: Dental Caries
Interventions: C16G2; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Kalispell, Montana • Salt Lake City, Utah

Conditions: COVID-19
Interventions: mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 13,553 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 161
States / cities: Huntsville, Alabama • Vestavia Hills, Alabama • Chandler, Arizona + 129 more

Search by objective public record fields.

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

Indoor Air Pollution and Children With Asthma: An Intervention Trial

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

A Study of LY2409021 Formulations in Healthy Participants

Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Day and Night Closed-loop in Young People With Type 1 Diabetes

Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients

SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Improving Community Ambulation After Hip Fracture

Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease

A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

Taste Acceptability of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

The T1D Parent Check-In: A Preventative Intervention

Internal Cues Versus External Cues for Eating and Activity

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19